IC
CLDX icon

Ikarian Capital’s Celldex Therapeutics CLDX Stock Holding History

Ikarian Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.62M Buy
+114,000
New +$3.11M 0.29% 75
2025
Q2 		– Sell
-17,800
Closed -$323K – 146
2025
Q1 		$323K Sell
17,800
-187,700
-91% -$4.19M 0.04% 128
2024
Q4 		$5.19M Sell
205,500
-100,000
-33% -$2.72M 0.71% 40
2024
Q3 		$10.4M Buy
+305,500
New +$11.6M 1.45% 18
2024
Q1 		– Sell
-200
Closed -$7.93K – 148
2023
Q4 		$7.93K Sell
200
-771
-79% -$22.7K ﹤0.01% 134
2023
Q3 		$2.67M Buy
+971
New +$30.4K 0.32% 71
2023
Q2 		– Sell
-110,000
Closed -$3.96M – 143
2023
Q1 		$3.96M Buy
+110,000
New +$4.75M 0.9% 40
2022
Q3 		– Sell
-616,700
Closed -$16.6M – 121
2022
Q2 		$16.6M Buy
616,700
+21,200
+4% +$616K 3.03% 6
2022
Q1 		$20.3M Buy
595,500
+144,300
+32% +$4.61M 2.67% 9
2021
Q4 		$17.4M Sell
451,200
-69,000
-13% -$3.01M 2.6% 7
2021
Q3 		$28.1M Buy
520,200
+504,200
+3,151% +$23.7M 1.98% 11
2021
Q2 		$535K Buy
+16,000
New +$439K 0.04% 185

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Ikarian Capital's CLDX Position: Q1 2026 in Review

Ikarian Capital opened a new position in Celldex Therapeutics (CLDX) in Q1 2026: 461,247 shares worth $14.6M. The stake represents 1.19% of the portfolio and ranks #21 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in CLDX as recently as Q1 2023.

Ikarian Capital first reported a position in CLDX in Q2 2020 and has held it in 13 quarters since. The position peaked at $23.9M in Q4 2020. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Ikarian Capital held 461,247 shares of Celldex Therapeutics worth $14.6M as of Q1 2026.
  • Celldex Therapeutics was a new Ikarian Capital position in Q1 2026.
  • Celldex Therapeutics made up 1.19% of Ikarian Capital's portfolio in Q1 2026, its #21 holding.
  • Ikarian Capital first reported a position in Celldex Therapeutics in Q2 2020 and has held it in 13 quarters since.
  • Ikarian Capital's Celldex Therapeutics position peaked at $23.9M in Q4 2020.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.